Cyclo‐oxygenases (COXs) catalyze the first committed step in the synthesis of the prostaglandins PGE₂, PGD₂, PGF_2α, PGI₂ and thomboxane A₂. Expression and enzymatic activity of COX‐2, the inducible isoform of COX, are observed in several neurological diseases and result in significant neuronal injury. The neurotoxic effect of COX‐2 is believed to occur through downstream effects of its prostaglandin products. In this study, we examined the function of PGD₂ and its two receptors DP1 and chemoattractant receptor‐homologous molecule expressed on Th2 cells (CRTH2) (DP2) in neuronal survival. PGD₂ is the most abundant prostaglandin in brain and regulates sleep, temperature and nociception. It signals through two distinct G protein‐coupled receptors, DP1 and DP2, that have opposing effects on cyclic AMP (cAMP) production. Physiological concentrations of PGD₂ potently and unexpectedly rescued neurons in paradigms of glutamate toxicity in cultured hippocampal neurons and organotypic slices. This effect was mimicked by the DP1‐selective agonist BW245C but not by the PGD₂ metabolite 15d‐PGJ₂, suggesting that neuroprotection was mediated by the DP1 receptor. Conversely, activation of the DP2 receptor promoted neuronal loss. The protein kinase A inhibitors H89 and KT5720 reversed the protective effect of PGD₂, indicating that PGD₂‐mediated neuroprotection was dependent on cAMP signaling. These studies indicate that activation of the PGD₂ DP1 receptor protects against excitotoxic injury in a cAMP‐dependent manner, consistent with recent studies of PGE₂ receptors that also suggest a neuroprotective effect of prostaglandin receptors. Taken together, these data support an emerging and paradoxical neuroprotective role of prostaglandins in the CNS.